In recent years, GLP-1 receptor agonists, also known as GLP-1s, have gained significant attention for their potential in promoting weight loss. These medications, including Ozempic and Saxenda, were originally developed for the treatment of type 2 diabetes but have also shown promising results in helping individuals achieve their weight loss goals.
Naturally with new medications, concerns about their safety and availability for obesity treatment are in the same conversation. That’s why we at Bodyline want to answer your questions, so we will explore the safety of GLP-1s for weight health and address common queries surrounding their use.
Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.
What is GLP-1?
GLP-1 is naturally produced in the intestines and plays a crucial role in regulating blood sugar levels, controlling appetite, and aiding in insulin production.
GLP-1 receptor agonists are medications that mimic the effects of the hormone glucagon-like peptide-1 (GLP-1) in the body and come in the form of injections administered once a week, though there are oral pill options available too. By activating GLP-1 receptors, GLP-1s help those with type-2 diabetes and obesity by boosting the regulation of blood sugar levels, slowing down digestion, reducing appetite, and therefore promoting life-changing weight loss.
Due to the incredible impact of GLP-1 receptor agonists on weight loss during clinical trials, pharmaceutical companies decided to make medications targeted at those currently living with obesity,
How do GLP-1s impact weight health?
GLP-1 receptor agonists have a multifaceted impact on weight health. By reducing appetite and increasing satiety, these medications can help individuals consume fewer calories, leading to weight loss. In a world where obesity is on track to impact 1 in 4 people by 2035, these game-changing medications have the potential to change lives.
GLP-1 receptor agonists have been shown to improve insulin sensitivity and glycaemic control, making them beneficial for individuals with type 2 diabetes or those at risk of developing diabetes. Furthermore, studies have shown that the medications can significantly decrease the risk of cardiovascular events in users. That means that heart attacks, heart disease, and strokes are less likely.
How safe are GLP-1s?
GLP-1 receptor agonists have been extensively studied for their safety and efficacy. Clinical trials have demonstrated their effectiveness in promoting weight loss and improving metabolic parameters.
However, like any medication, GLP-1s may have potential side effects. The most common side effects reported include gastrointestinal symptoms such as nausea, constipation, diarrhoea, and heartburn. These side effects are generally mild and tend to subside over time.
Rare side effects, such as hypoglycaemia (low blood sugar), pancreatitis, and thyroid cancer, have been reported but are uncommon. This is why it is vital that GLP-1s should be used under proper medical supervision within a fully supported medical weight loss programme to ensure their safety and effectiveness.
Programmes like Bodyline’s can keep track of side effects, monitor efficacy, and can alter prescriptions and dosages as needed.
Are GLP-1s available for obesity treatment?
GLP-1s have shown significant potential for obesity treatment. Some GLP-1 receptor agonists, such as semaglutide (Ozempic rebranded as WeGovy) and liraglutide (Saxenda), have been approved for both type 2 diabetes and obesity treatment for some time now, while tirzepatide (Mounjaro) has only just been approved in November 2023. These medications have demonstrated significant weight loss effects in clinical trials, particularly Mounjaro which has been dubbed the ‘king kong’ of weight loss treatment.
However, it is essential to consult with a weight health professional clinic, such as Bodyline, to determine the most suitable option and ensure the proper use of GLP-1s for obesity treatment. If you have certain medical conditions or take contraindicated medications, you may not be eligible for GLP-1s to treat obesity.
Luckily, Bodyline offers a wide range of medical weight loss treatments that are guaranteed to see significant weight loss. Read more about what we offer here.
Can I get GLP-1s with Bodyline?
Bodyline offers comprehensive medical weight loss programs that incorporate GLP-1s as part of the treatment. These programs provide personalized care and guidance to individuals seeking to achieve weight loss goals. Bodyline’s experienced healthcare professionals assess each individual’s unique needs and evaluate the suitability of GLP-1s as part of the weight loss journey. With proper medical supervision, support, and monitoring, Bodyline ensures the safe and effective use of GLP-1s for weight health.
Semaglutide (Ozempic branded as WeGovy) is an injectable therapy that has been approved for both type 2 diabetes and obesity treatment. Manufactured by Novo Nordisk, Ozempic was originally marketed as a diabetes treatment, but due to the significant weight loss effects demonstrated in clinical trials, they began producing a remarketed version, WeGovy, specifically to treat obesity. Users have seen an average 15% body weight reduction in studies over a 68-week period when used alongside diet and exercise.
Liraglutide (Saxenda) is also an injectable medication approved for the treatment of obesity but is self-administered once a day. It helps reduce appetite and promotes weight loss when used as part of a comprehensive weight loss programme. Here at Bodyline, we have been prescribing Saxenda as part of our medical weight loss treatment plans for almost 10 years, helping clients lose 5-10% of their body weight on average safely and effectively.
Tirzepatide (Mounjaro) is a new injectable medication, that has JUST been approved for obesity treatment by MHRA as of November 2023. Tirzepatide has shown groundbreaking results in promoting weight loss and controlling blood sugar levels. Clinical trials saw that over 85% of users saw a loss of between 5-20% of their body weight, far surpassing the effectiveness of other GLP-1 injectable medications available.
GLP-1s have emerged as promising medications for weight health. Their ability to promote weight loss, improve metabolic parameters, and regulate blood sugar levels makes them valuable tools in comprehensive weight loss programs. While GLP-1s may have potential side effects, their safety and efficacy have been well-established through clinical trials.
We must stress how important it is to use GLP-1s under proper medical supervision to ensure their safe and effective use. Remember, weight health is a complex journey, and it is essential to approach it holistically. Alongside the use of GLP-1s, incorporating healthy eating habits, regular physical activity, and lifestyle modifications are crucial for long-term success. With the guidance and support of medical weight loss programs like Bodyline, you can embark on a safe and effective weight loss journey that prioritizes your well-being. Contact Bodyline to find out more.
